Related Experiment Video
Updated: May 19, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Everolimus-eluting stents: update on current clinical studies
Dominic J Allocco1, Anita A Joshi, Keith D Dawkins
1Boston Scientific Corporation, Natick, MA, USA.
Medical Devices (Auckland, N.Z.)
|August 24, 2012
Summary
Everolimus-eluting stents (EES) demonstrate superior outcomes compared to paclitaxel-eluting stents (PES), showing reduced restenosis and myocardial infarction. This review analyzes clinical data supporting EES use in coronary interventions.
Area of Science:
- Cardiology
- Biomedical Engineering
- Interventional Cardiology
Background:
- Everolimus-eluting stents (EES) are the most frequently used coronary stents globally.
- Previous stent generations, such as paclitaxel-eluting stents (PES), have associated risks and limitations.
Purpose of the Study:
- To review and analyze clinical data supporting the efficacy and safety of EES.
- To compare EES performance against other coronary stent types, particularly PES.
Main Methods:
- Analysis of published, randomized, controlled trials (RCTs) evaluating EES.
- Subgroup analysis to assess EES performance across different patient populations.
Main Results:
- EES show significantly lower rates of restenosis, stent thrombosis, and periprocedural myocardial infarction compared to PES.
- Adverse event rates for EES were lower than PES across most subgroups, except in patients with diabetes mellitus.
- Limited but positive data exist comparing EES to sirolimus-eluting and zotarolimus-eluting stents.
Conclusions:
- EES offer an improved safety and efficacy profile for coronary artery interventions compared to earlier stent generations.
- Next-generation EES maintain this favorable profile with enhanced mechanical properties and radiopacity.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...